Skip to main content
Caplight Logo









xCystence Bio

xCystence Bio

Private
MelbourneHealthcare & Life Scienceshttps://www.xcystencebio.com/

Last Round

Pre Seed

Mar 30, 2026

Total Funding Raised

$500,000

Company Overview

xCystence Bio is a biotechnology company developing targeted protein degraders to treat Autosomal Dominant Polycystic Kidney Disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted protein degradationTPDADPKDautosomal dominant polycystic kidney diseaseAURKAAurora kinase Adrug discoverybiotech startupsmall molecule drugskidney disease therapeuticsprotein degraderprecision medicinepreclinical developmentbiotech spin-outdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

xCystence Bio Comparables

Compare xCystence Bio with similar companies based on industry and business-model similarity.

xCystence Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mironid
79%
Eli Lilly and Company
70%
Regulus Therapeutics Inc.
66%

xCystence Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedMar 30, 2026
GrantSep 4, 2025
GrantMay 30, 2023

xCystence Bio Investors

Notable investors and investment history

xCystence Bio investors
InvestorRounds
CUREatorGrant
BioCuratePre Seed
Monash Investment HoldingsPre Seed
UniseedPre Seed
Breakthrough VictoriaPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 30, 2023

    $330K grant received from CUREator.

xCystence Bio Filings

Explore SEC and related filing metadata, where available.

xCystence Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about xCystence Bio's valuation, stock price, and market status.

Is xCystence Bio a public or private company?

xCystence Bio is a private company.

What is the current stock price of xCystence Bio?

xCystence Bio is a private company with no public stock price. No recent secondary market data is available.

How much is xCystence Bio worth (valuation)?

Valuation information for xCystence Bio is not publicly available.

Can I buy xCystence Bio stock?

xCystence Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was xCystence Bio's last funding round?

xCystence Bio's most recent funding round was Pre Seed on March 30, 2026.

Who are the main investors in xCystence Bio?

Key investors in xCystence Bio include Uniseed.

Will xCystence Bio IPO soon?

No public IPO plans have been announced for xCystence Bio.

How can I track xCystence Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor xCystence Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMelbourne
Year Founded2023
Last FundingMar 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?